<DOC>
	<DOCNO>NCT01103843</DOCNO>
	<brief_summary>- The purpose study determine level inhibition platelet activation approve thienopyridine ( clopidogrel prasugrel ) aspirin regimen set drug elute coronary stent implantation . - In subject high residual level platelet reactivity receive either maintenance loading dose either clopidogrel prasugrel , cross thienopyridine treatment alternate medication occur . - The study test hypothesis adequate platelet inhibition occur subject high level platelet reactivity subsequently switch clopidogrel prasugrel ( load maintenance dose ) without increase episode bleed MACE event discharge 30 day post Percutaneous Coronary Intervention ( PCI ) .</brief_summary>
	<brief_title>Plavix , Prasugrel Drug Eluting Stents Pilot Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Subject present clinically indicate PCI implantation least one drugeluting stent . No plan use Glycoprotein IIb/IIIa inhibitor PCI procedure . Subject must take aspirin enteric coat aspirin 81 mg325 mg daily . Willing participate sign inform consent . Subject old 75 year age . Subject weight 60 kg less . Subject receive intravenous eptifibatide tirofiban within 48 hour prior PCI abciximab within 14 day PCI . Subject take warfarin clinical indication resume warfarin post PCI indication . Subject currently require daily treatment NSAID COX2 inhibitor . Subject know platelet disorder . Subject know active pathological bleeding heighten risk bleed include limited : gastrointestinal bleeding within 6 month , recent surgery trauma . Subject history stroke TIA Subject prePCI hematocrit platelet count outside range validate Verify Now P2Y12 test ( 3352 % 119.000502.000/Î¼L , respectively ) . Subject history hepatic impairment Subject know NYHA Class III great heart failure . Inability subject provide inform consent . Subject know hypersensitivity contraindication clopidogrel , prasugrel ASA , would result inability patient adhere trial protocol . Presence valvular heart disease leave main coronary artery stenosis urgent need CABG .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>prasugrel</keyword>
	<keyword>Verify Now</keyword>
	<keyword>PRU measurement</keyword>
	<keyword>Drug elute stent ( EDS )</keyword>
	<keyword>P2Y12</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>